$4,118.74 0.75%
ETH · 4w

Ethereum killers or just pretenders? But Ether remains king for now 👑

The term “Ethereum killer” is beginning to pick up the pace once again in the cryptocurrency markets as the native tokens of several competing blockchain networks are posting significant gains during September. For any alternative network to be considered as a part of this category, it needs to have one essential feature that serves as the backbone of the Ethereum network: smart contracts.

Keeping this in mind, the most prominent blockchain networks by market capitalization that usually come under this purview are Cardano (ADA), Solana (SOL), Binance Smart Chain (BSC), Polkadot (DOT), and Terra(LUNA). The native tokens of these networks have been on an absolute tear this year. Most recently, Solana (SOL) has been in the spotlight after the bulls carrying its rally continued even in the face of a marketwide selloff on Sept. 8 that brought Bitcoin back below the $50,000 mark.

SOL has more than doubled in price over the last 30 days but has since declined to trade around the $155 mark. The token has posted over 300% gains over the last 90 days with an extraordinary 7,871.16% gains year-to-date (YTD). In comparison, these gains dwarf ETH’s 63.77% 90-day gains and 385.36% YTD gains. Ethereum's market capitalization is currently at around $400 billion which is nearly 9 times SOL’s $47 billion market cap.

Ethereum killer tokens post gains

Several networks have shown promising prospects and gains. Cardano recently completed its Alonzo hard fork that launched Plutus-powered smart contracts on the network that would allow it to host decentralized finance (DeFi) and Web 3.0 applications. Even though its native token, ADA, showed a lackluster response to this milestone in the project’s roadmap, it has still experienced a substantial rise this year. ADA trades at around $2.40, posting 74.16% gains in the last 90 days and 1,273.86% gains YTD.

Marie Tatibouet, chief marketing officer at — a cryptocurrency exchange — outlined to Cointelegra...

Continue on
Recent news